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ABSTRACT
Objective: The aim of the present study was to formulate and optimize budesonide nanoemulsions for targeting inflammation.
Methods: Budesonide is only found in individuals that have used or taken this drug. It is a glucocorticoid used in the management of asthma, the 
treatment of various skin disorders, and allergic rhinitis. The exact mechanism of the action of budesonide in the treatment of Crohn’s disease is not 
fully understood. However, being a glucocorticosteroid, budesonide has a high local anti-inflammatory effect. The formulation was optimized for 
different components and the solubility study for the oil in surfactant and cosurfactant mix ratio was optimized using ternary phase diagram.
Results: The surfactant mix ratio was optimized as 1:3 where the maximum concentration of the oil has solubilized and the nanoemulsion area was 
increased.
Conclusion: Budesonide nanoemulsion for targeting inflammation and the pseudoternary phase diagram for the solubility studies and the components 
of different phases were optimized and achieved through this study.
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INTRODUCTION
METHODS
Budesonide (Hetero Lab Pvt., Ltd., gift sample), polyoxyl 35, castor oil 
(SD Fine Chem, Ltd., Mumbai), Tween 80 (SD Fine Chem Ltd., Mumbai), 
polyethylene glycol (PEG) 400 (SD Fine Chem, Ltd., Mumbai), ethanol 
(SD Fine Chem, Ltd., Mumbai), Probe Sonicator, Bath Sonicator, 
Magnetic Stirrer, and high-performance liquid chromatography (HPLC) 
were used.
Preformulation studies
The preformulation study was mainly done to determine the physical, 
chemical, and various pharmaceutical properties [14] of all the 
components (including drug) alone and also when combined together 
in the formulation. The main objective of the preformulation study 




The optimization of oil [14] can be done by adding excess of drug in 
2 ml of fixed oils such as polyoxyl 35 oil, castor oil, super refined olive 
oil, medium chain triglyceride (palm kernel oil), soya bean oil, Labrafac 
propylene glycol (PG), triacetin, and isopropyl myristate separately 
in a 5 ml capacity three stopper vials for 1 week–1 month and mixed 
using vortex mixer. The samples were then centrifuged at 3000 rpm for 
15 min. The supernatant was taken and then filtered. The concentration 
of budesonide in these oils was determined using HPLC.
Optimization of surfactant
The surfactant selection [16] was done by adding 4 ml of selected oil to 
2.5 ml of surfactant solution (15% V/V surfactant in water) and mixed 
using vortex mixer. The mixing was performed until a clear solution 
obtained. In the similar way, cosurfactant was also optimized.
Preparation of pseudoternary phase diagram
On the basis of optimization [17] studies, polyoxyl 35 was selected 
oil phase and tween 80 and ethanol were selected as surfactant and 
cosurfactant, respectively. Distilled water was used as aqueous phase. 
The surfactant and cosurfactant were mixed at different mass ratios 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i1.28686
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Nanoemulsions  [1]  are  high  solubilizing  and  drug 
protection features have the potential to deliver proteins as well 
as  other  new  (or  traditional)  active  drug  compounds. 
Although  authors  have  suggested  using  nanoemulsion 
formulations  for  inflammation  [2-7].  Budesonide 
(16,17-butylidenebis(oxy)-11,21-dihydroxypregna-1,4-
diene-3,20-dione) is a synthetic glucocorticoid steroid used in 
the  treatment  of  asthma  and  an  inflammatory  bowel  disease  [9]. 
Molecular  weight  of  budesonide  is  430.5,  log  p  values  are  3.2, 
biopharmaceutical  classification  system  Class  II  and 
practically insoluble in water (28 µg/mL) [10]. It is a potent
 non-halogenated corticosteroid and has a relative glucocorticoid 
receptor affinity of 935 compared with 100 for dexamethasone and 
a 200-fold higher glucocorticoid receptor affinity and a 1000-fold 
higher  topical  anti-inflammatory  potency than cortisol  [11]. 
Budesonide is completely absorbed from the gastrointestinal 
tract;  however,  its  bioavailability  is  around  10%  due  to  hepatic 
first-pass effect [12]. Due to degradation of budesonide in the liver 
easily,  an  alternative  way  should  be  developed  to  avoid  the 
first-pass effect, thereby the cellular uptake in the site of action
 is  enhanced  [13].  The  droplet  size  of  the  nanoemulsion 
typically  falls  in  the range of  20–30 nm and shows a  narrow 
sized distribution. It consists of two phases, one is aqueous phase and 
the  other  is  oil  phase.  The  excipient  to  be  used  is  selected  using 
preformulation  studies.  The  optimization  of  the  oil,  surfactant,  and 
water  in  the  formulation  is  done  by  solubility  study.  The  optimum 
concentration of the oil  that could be solubilized with the surfactant 
mix (Smix) is optimized using pseudo ternary phase diagram.
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(1:1, 1:2, and 1:3). These ratios were chosen in increasing concentration 
of cosurfactant with respect to surfactant for a detailed study of phase 
diagram. For each phase diagram, oil and Smix at specific ratios were 
mixed thoroughly at different mass ratios from 1:1 to 1:3 in different 
glass vials. 10 different combinations of oil and Smix were made so that 
maximum ratios were covered for the study.
The ternary phase diagram for oil, Smix [18], and aqueous phase was 
developed using aqueous filtration method. To the oil and Smix mixture, 
aqueous phase is added slowly and titrated. Visual observations 
were made for emulsions. The physical state was marked on the 
pseudoternary phase diagram with one axis representing water, the 
second one representing oil phase, and third representing a mixture of 




Lipophilic drugs were preferably solubilized in oil-in-water (O/W) 
nanoemulsion where W/O system seems to be better choice for 
hydrophilic drugs. The volume of the formulation should be minimized 
as much as possible to deliver the therapeutic dose. Solubility of the 
drug in the oil phase was an important criterion for the selection of oils. 
The surfactant and cosurfactant are contributing to drug solubilization.
The solubility of budesonide in different oils is shown in Table 1. The 
solubility of drug is found to be highest in polyoxyl 35 as compared 
to other oils. The castor oil was selected as the oil phase for the 
development of nanoemulsion formulation.
Optimization of surfactants
It is important to determine the surfactant concentration in the 
formulation. O/W nanoemulsion dosage forms [19] for oral or parental 
use based on non-ionic surfactants are likely to offer in vivo stability. 
Another important criterion is the selection of cosurfactant to lower the 
necessary interfacial energy to form the nanoemulsion, consequently 
improving the solubility. In the present study, tween 80, ethanol, PG, 
tween 20, tween 80, Transcutol, PEG 200, and PEG 400 were chosen for 
screening. Tween 80 and ethanol were selected as the surfactant and 
cosurfactant due to its high miscibility with oil phase.
Preparation of pseudoternary phase diagram
Pseudoternary phase diagram was constructed separately for each 
Smix ratio [20] so that O/W nanoemulsion region could be identified 
Fig. 1: Construction of pseudoternary phase diagram with Smix 
ratio 1:1
Fig. 2: Construction of pseudoternary phase diagram with Smix 
ratio 1:2
Table 1: Composition of the solubility of budesonide in various oils, surfactant, and cosurfactant at 70°C (mean±SD, n=3)
Oil Solubility (mg/ml) Surfactant Solubility (mg/ml)
Castor oil 52±0.1 Tween 80 29±1.3
Polyoxyl 35 53±0.1 Ethanol 30±1.3
Super refined olive oil 7±0.1 PG 0.6±1.3
Soya bean oil 2±0.05 Tween 20 15±0.5
MCT (palm kernel oil) 8±0.4 Tween 80 5±0.02
Labrafac PG 1±0.04 Transcutol 39±0.2
Triacetin 3±0.6 PEG 200 35±0.5
Isopropyl myristate 6±0.05 PEG 400 30±0.4
PEG: Polyethylene glycol, MCT: Medium chain triglyceride, PG: Propylene glycol, SD: Standard deviation
Fig. 3: Construction of pseudoternary phase diagram with Smix 
ratio 1:3
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and optimized. The relationship between the phase behavior of the 
surfactant mixture and other components is captured using phase 
diagram. In Fig. 1, the Smix ratio was 1:1 where the nanoemulsion 
area has been narrow when the surfactant ratio is high. In Fig. 2, the 
surfactant and cosurfactant were mixed in same ratio 1:2 where 
the maximum concentration of oil 85% has been solubilized and the 
nanoemulsion area increased. It may be due to further reduction of 
the interfacial tension, increasing the fluidity of the interface, thereby 
increasing the entropy of the system. In Fig. 3, the ratio was 1:3 where the 
cosurfactant increased and the nanoemulsion area has been decreased 
which states that high amount of cosurfactant mixture may not have the 
effect on interfacial tension. Hence, using a constructed phase diagram, 
the optimum ratios of the components for nanoemulsion which would 
remain stable and prevent drug precipitation over infinite dilution were 
selected as 85 μl.
CONCLUSION
Pseudoternary phase diagram for the solubility studies was constructed, 
and the components of different phases were optimized for further 
formulation of budesonide into nanoemulsion as anti-inflammatory 
agent.
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